LOKELMATM Sodium Zirconium Cyclosilicate

SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1

*In an emergency situation, standard of care should be used in line with local or national guidelines
Clinical trials with LOKELMA have not included exposure longer than one year

Clinical Studies

HARMONIZE Pivotal Trial

Swift serum K+ reduction as early as 1 hour with one dose*

In the 48-hour, open-label phase of the study:

  • One dose (10 g) of LOKELMA significantly reduced the mean serum K+ level after 1 hour (-0.2 mmol/L compared with baseline, 95% Cl, -0.3 to -0.2)*1,2
  • Median time to normokalaemia was 2.2 hours (interquartile range, 1.0–22.3)2
    • Mean baseline serum K+ was 5.6 mmol/L (standard deviation, 0.4 mmol/L)2
  • Typically, LOKELMA normalised K+ levels within 48 hours1,2 
    • 66% of patients achieved normokalaemia at 24 hours1
    • 88% of patients achieved normokalaemia at 48 hours1
  • Responses were greater in patients with more severe hyperkalaemia; serum K+ fell 0.8, 1.2 and 1.5 mmol/L
    at 48 hours in patients with baseline serum K+ <5.5, 5.5–5.9 and ≥6 mmol/L, respectively1,2

    *In an emergency situation, standard of care should be used in line with local or national guidelines

 

Mean serum K+ levels with LOKELMA 10 g three times daily for 48 hours (N=258)2

Graph of mean serum K+ levels with LOKELMA<sup>TM</sup> hyperkalaemia treatment
Graph of mean serum K+ levels with LOKELMA<sup>TM</sup> hyperkalaemia treatment

Adapted from Kosiborod M, et al. JAMA. 2014;312(21):2223-2233.